Ameriprise
AUPH icon

Ameriprise’s Aurinia Pharmaceuticals AUPH Stock Holding History

Ameriprise’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$188K Sell
11,053
-33,395
-75% -$533K ﹤0.01% 3970
2026
Q1 		$659K Buy
44,448
+33,845
+319% +$495K ﹤0.01% 3475
2025
Q4 		$169K Sell
10,603
-5
-0% -$71 ﹤0.01% 3953
2025
Q3 		$117K Sell
10,608
-123,695
-92% -$1.35M ﹤0.01% 3965
2025
Q2 		$1.14M Buy
134,303
+102,888
+328% +$825K ﹤0.01% 3211
2025
Q1 		$253K Sell
31,415
-6,381
-17% -$51.7K ﹤0.01% 3727
2024
Q4 		$339K Buy
37,796
+26,981
+249% +$220K ﹤0.01% 3678
2024
Q3 		$79.3K Buy
10,815
+130
+1% +$806 ﹤0.01% 3857
2024
Q2 		$61K Buy
+10,685
New +$56.3K ﹤0.01% 3809
2020
Q1 		– Sell
-146,841
Closed -$2.98M – 3640
2019
Q4 		$2.98M Sell
146,841
-212,250
-59% -$1.96M ﹤0.01% 2525
2019
Q3 		$1.92M Sell
359,091
-3,248
-0.9% -$19.7K ﹤0.01% 2713
2019
Q2 		$2.38M Sell
362,339
-3,171
-0.9% -$20.2K ﹤0.01% 2643
2019
Q1 		$2.38M Sell
365,510
-1,696
-0.5% -$11.3K ﹤0.01% 2661
2018
Q4 		$2.5M Sell
367,206
-2,146
-0.6% -$12.4K ﹤0.01% 2544
2018
Q3 		$2.45M Buy
369,352
+69,360
+23% +$389K ﹤0.01% 2738
2018
Q2 		$1.69M Buy
299,992
+40,138
+15% +$224K ﹤0.01% 2798
2018
Q1 		$1.35M Buy
259,854
+22,501
+9% +$120K ﹤0.01% 2845
2017
Q4 		$1.07M Buy
237,353
+25,784
+12% +$143K ﹤0.01% 2948
2017
Q3 		$1.33M Buy
211,569
+60,101
+40% +$379K ﹤0.01% 2834
2017
Q2 		$928K Buy
+151,468
New +$1.02M ﹤0.01% 2976

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise's AUPH Position: Q2 2026 in Review

Ameriprise reduced its Aurinia Pharmaceuticals (AUPH) stake by 75% in Q2 2026, selling an estimated $533K and leaving 11,053 shares worth $188K. The position accounts for ﹤0.01% of the portfolio, ranked #3970.

Ameriprise first reported a position in AUPH in Q2 2017 and has held it in 20 quarters since. The position peaked at $2.98M in Q4 2019. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Ameriprise held 11,053 shares of Aurinia Pharmaceuticals worth $188K as of Q2 2026.
  • Ameriprise sold 33,395 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $533K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3970 holding.
  • Ameriprise first reported a position in Aurinia Pharmaceuticals in Q2 2017 and has held it in 20 quarters since.
  • Ameriprise's Aurinia Pharmaceuticals position peaked at $2.98M in Q4 2019.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.